Light Adjustable Lens for Astigmatism
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to correct astigmatism, a common vision problem causing blurriness, in individuals undergoing cataract or lens replacement surgery. It combines two treatments: precise laser cuts in the cornea, known as arcuate incisions, and a special lens called the Light Adjustable Lens (LAL), which can be adjusted after surgery to enhance vision. The trial evaluates the effectiveness of these treatments together, focusing on vision clarity and patient satisfaction. Individuals planning lens replacement surgery and having certain types of astigmatism may be suitable candidates. As a Phase 4 trial, the treatment has already received FDA approval and proven effective, aiming to understand its benefits for more patients.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have a known sensitivity to the medications planned for the study, you may not be eligible to participate.
What is the safety track record for the Light Adjustable Lens and arcuate incisions?
Research has shown that the Light Adjustable Lens (LAL) is generally well-tolerated. In one study with 600 participants, those who received the LAL were twice as likely to achieve excellent vision results compared to standard treatments. Specifically, 92% of participants attained their desired vision correction with high accuracy, suggesting that the LAL is both safe and effective.
For femtosecond laser arcuate incisions, research indicates they are as safe as traditional manual methods. In a study with 23 participants, only a small amount of remaining astigmatism was observed after surgery, demonstrating effective correction with no significant side effects.
Overall, both treatments in this trial have proven safe and successful in previous studies, with minimal adverse effects.12345Why are researchers enthusiastic about this study treatment?
Researchers are excited about the Light Adjustable Lens (LAL) for astigmatism because it offers a customizable approach to vision correction. Unlike traditional treatments like fixed lenses or glasses, the LAL can be precisely adjusted after implantation to fine-tune vision correction, allowing for personalized adjustments based on individual healing and visual needs. This adaptability is achieved through specialized light treatments that reshape the lens, offering a level of precision and personalization not available with standard options. With this innovative approach, patients have the potential for improved vision outcomes tailored specifically to their eyes.
What evidence suggests that this trial's treatments could be effective for astigmatism?
Research has shown that the Light Adjustable Lens (LAL), one of the treatments in this trial, effectively improves vision. Studies have found that it accurately corrects vision problems, helping people see clearly at various distances. This lens can be adjusted after surgery to fine-tune vision, enhancing its effectiveness.
Arcuate incisions, another treatment option in this trial, involve small cuts made in the eye to help reshape it. Studies show they effectively reduce astigmatism, a condition that causes blurred vision because the cornea is not perfectly round. These incisions remain stable and provide lasting improvements. Together, both treatments in this trial aim to enhance vision by addressing different aspects of the eye's shape and focus.16789Who Is on the Research Team?
Priya Mathews, MD
Principal Investigator
Center For Sight - Clinical Studies
Are You a Good Fit for This Trial?
This trial is for individuals with astigmatism or mixed astigmatism who are undergoing cataract or lens exchange surgery. Participants should be interested in correcting their vision using a combination of laser technology and an adjustable lens implant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo femtosecond laser arcuate corneal relaxing incisions combined with Light Adjustable Lens implantation
Postoperative Assessment
Postoperative assessments focus on residual refractive astigmatism, visual outcomes, patient satisfaction, and incidence of adverse events
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Arcuate Incisions
- Light Adjustable Lens (LAL)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Center For Sight
Lead Sponsor
LensAR Incorporated
Industry Sponsor